Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study

Wu, Jian; Liu, Jun; Zhao, Xinguo; Liu, Chengyuan; Wang, Wei; Wang, Dawei; Xu, Wei; Zhang, Chunyu; Yu, Jiong; Jiang, Bin; H, Cao; Li, Lanjuan

doi:10.1093/cid/ciaa199

Cited by 607 publications

(648 citation statements)

References 23 publications

Supporting

Mentioning

538

Contrasting

Unclassified

Order By: Relevance

“…Our patients had the same other symptoms (other than ENT symptoms) as those reported in other studies [2][3][4][5][6][7]. However, just like Lechien et al, we observed that diarrhea was reported in more than 50% of patients.…”

Section: -Related Olfactory Dysfunctionsupporting

confidence: 86%

“…Anosmia was never the first or second symptom to develop, but it was the third symptom in 38% (22/52) of cases. Anosmia developed 4.4 (±1.9 [1][2][3][4][5][6][7][8]) days after infection onset.…”

Section: Resultsmentioning

confidence: 99%

“…Until recently, ENT symptoms had not been reported with COVID-19, except for nasal congestion and rhinorrhea [2][3][4][5][6][7][8]. However, 54 (47%) of our 114 COVID-19 patients reported anosmia.…”

Section: -Related Olfactory Dysfunctionmentioning

confidence: 93%

“…Fever, cough, fatigue, and myalgia are usually the main symptoms. The expression of COVID-19 ILI seems non-specific; no specific symptom can lead to suspecting a case without any notion of exposure [2][3][4][5][6][7]. A major French cluster of COVID-19 began on March 1, 2020 in the city of Mulhouse, France (less than 30 miles from our hospital).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Features of anosmia in COVID-19

Klopfenstein

Kadiane-Oussou

Toko

et al. 2020

Médecine et Maladies Infectieuses

390

389

View full text Add to dashboard Cite

Page 2 of 11 J o u r n a l P r e -p r o o f Background. Medical publications about anosmia with COVID-19 are scarce. We aimed to describe the prevalence and features of anosmia in COVID-19 patients. Methods. We retrospectively included COVID-19 patients with anosmia between March 1 andMarch 17, 2020. We used SARS-CoV-2 real time PCR in respiratory samples to confirm the cases.Results. Fifty-four of 114 patients (47%) with confirmed COVID-19 reported anosmia. Mean age of the 54 patients was 47 (±16) years; 67% were females and 37% were hospitalized. The median Charlson comorbidity index was 0.70 (±1.6 [0-7]). Forty-six patients (85%) had dysgeusia and 28% presented with pneumonia. Anosmia began 4.4 (±1.9 [1-8]) days after infection onset. The mean duration of anosmia was 8.9 (±6.3 [1-21]) days and 98% of patients recovered within 28 days. Conclusions.Anosmia was present in half of our European COVID-19 patients and was often associated with dysgeusia.

show abstract

Section: -Related Olfactory Dysfunctionsupporting

confidence: 86%

Section: Resultsmentioning

confidence: 99%

Section: -Related Olfactory Dysfunctionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Features of anosmia in COVID-19

Klopfenstein

Kadiane-Oussou

Toko

et al. 2020

Médecine et Maladies Infectieuses

390

389

View full text Add to dashboard Cite

show abstract

“…There was no significant association between oxygenation index and creatinine as well as uric acid among COVID-19 patients without AKI (Fig.1D-E). AKI was defined as any of renal functional indices beyond normal range 14 Note: Compared with "Mild", *P<0.05, **P<0.01, ***P<0.001; compared with "Severe", #P<0.05, ##P<0.01, ###P<0.001. a AKI was defined as any of renal functional indices beyond normal range.…”

Section: Aki Is Companied At the Early Stage Of Covid-19 Pneumoniamentioning

confidence: 99%

Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis

Fei

et al. 2020

Preprint

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a newly emerged infection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has been pandemic all over the world. This study described acute kidney injury (AKI) at early stage of COVID-19 and its clinical significance. Three-hundred and fifty-five COVID-19 patients with were recruited and clinical data were collected from electronic medical records. Patient's prognosis was tracked and risk factors of AKI was analyzed. Of 355 COVID-19 patients, common, severe and critical ill cases accounted for 63.1%, 16.9% and 20.0%, respectively. On admission, 56 (15.8%) patients were with AKI. Although AKI was more common in critical ill patients with COVID-19, there was no significant association between oxygenation index and renal functional indices among COVID-19 patients with AKI. By multivariate logistic regression, male, older age and comorbidity with diabetes were three important independent risk factors predicting AKI among COVID-19 patients. Among 56 COVID-19 patients with AKI, 33.9% were died on mean 10.9 day after hospitalization. Fatality rate was obviously higher among COVID-+19 patients with AKI than those without AKI (RR=7.08, P<0.001). In conclusion, male elderly COVID-19 patients with diabetes are more susceptible to AKI. AKI at early stage may be a negative prognostic indicator for COVID-19.

show abstract

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia

et al. 2021

View full text Add to dashboard Cite

; for the CORIMUNO-19 Collaborative Group IMPORTANCE Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus disease 2019 (COVID-19). OBJECTIVE To determine whether tocilizumab (TCZ) improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia. DESIGN, SETTING, AND PARTICPANTS This cohort-embedded, investigator-initiated, multicenter, open-label, bayesian randomized clinical trial investigating patients with COVID-19 and moderate or severe pneumonia requiring at least 3 L/min of oxygen but without ventilation or admission to the intensive care unit was conducted between March 31, 2020, to April 18, 2020, with follow-up through 28 days. Patients were recruited from 9 university hospitals in France. Analyses were performed on an intention-to-treat basis with no correction for multiplicity for secondary outcomes. INTERVENTIONS Patients were randomly assigned to receive TCZ, 8 mg/kg, intravenously plus usual care on day 1 and on day 3 if clinically indicated (TCZ group) or to receive usual care alone (UC group). Usual care included antibiotic agents, antiviral agents, corticosteroids, vasopressor support, and anticoagulants. MAIN OUTCOMES AND MEASURES Primary outcomes were scores higher than 5 on the World Health Organization 10-point Clinical Progression Scale (WHO-CPS) on day 4 and survival without need of ventilation (including noninvasive ventilation) at day 14. Secondary outcomes were clinical status assessed with the WHO-CPS scores at day 7 and day 14, overall survival, time to discharge, time to oxygen supply independency, biological factors such as C-reactive protein level, and adverse events. RESULTS Of 131 patients, 64 patients were randomly assigned to the TCZ group and 67 to UC group; 1 patient in the TCZ group withdrew consent and was not included in the analysis. Of the 130 patients, 42 were women (32%), and median (interquartile range) age was 64 (57.1-74.3) years. In the TCZ group, 12 patients had a WHO-CPS score greater than 5 at day 4 vs 19 in the UC group (median posterior absolute risk difference [ARD] −9.0%; 90% credible interval [CrI], −21.0 to 3.1), with a posterior probability of negative ARD of 89.0% not achieving the 95% predefined efficacy threshold. At day 14, 12% (95% CI −28% to 4%) fewer patients needed noninvasive ventilation (NIV) or mechanical ventilation (MV) or died in the TCZ group than in the UC group (24% vs 36%, median posterior hazard ratio [HR] 0.58; 90% CrI, 0.33-1.00), with a posterior probability of HR less than 1 of 95.0%, achieving the predefined efficacy threshold. The HR for MV or death was 0.58 (90% CrI, 0.30 to 1.09). At day 28, 7 patients had died in the TCZ group and 8 in the UC group (adjusted HR, 0.92; 95% CI 0.33-2.53). Serious adverse events occurred in 20 (32%) patients in the TCZ group and 29 (43%) in the UC group (P = .21). CONCLUSIONS AND RELEVANCE In this randomized clinical trial of patients with COVID-19 and pneumonia requiring oxygen support but not admitted to the intensive care...

show abstract

Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study

Cited by 607 publications

References 23 publications

Features of anosmia in COVID-19

Features of anosmia in COVID-19

Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia

Contact Info

Product

Resources

About